V. Dequattro et Dp. Lee, FIXED-DOSE COMBINATION THERAPY WITH TRANDOLAPRIL AND VERAPAMIL SR IS EFFECTIVE IN PRIMARY HYPERTENSION, American journal of hypertension, 10(7), 1997, pp. 138-145
We assessed the efficacy of monotherapy with trandolapril, an angioten
sin converting enzyme (ACE) inhibitor, and of verapamil slow-release (
SR), a calcium antagonist, each in a range of three doses as monothera
py, and in the nine possible combinations of therapy in patients with
stage I to III diastolic hypertension. After 4 weeks of single-blind p
lacebo, 746 patients in 39 study centers were randomized to one of the
16 double-blind treatments for 6 weeks (placebo; verapamil SR monothe
rapy 120, 180, or 240 mg; trandolapril monotherapy 0.5, 2, or 8 mg; an
d trandolapril/verapamil SR combinations 0.5/120, 0.5/180, 0.5/240, 2/
120, 2/180, 2/240, 8/120, 8/180, or 8/240 mg. Both mono- and combinati
on therapies achieved the primary efficacy parameters: lowered supine
diastolic blood pressure (at trough) more than placebo, P <.01 (except
0.5 mg trandolapril, 0.5/180 and 2/120 combinations, P <.05, and the
120 mg verapamil SR, P = NS). The therapies yielded a trough to peak r
atio of >0.52 and had higher percentages of responders as compared wit
h placebo (P <.01, <.05). Supine systolic blood pressures were lowered
more by combination therapy than the respective monotherapies, P <.05
, P <.01, except the 8/120 combination. Combination therapy was more e
ffective than monotherapy for sitting diastolic blood pressure, P <.05
. The percentage of patients with adverse reactions were similar for m
ono- and combination therapy. Trandolapril had a greater ''apparent''
incremental effect on the systolic blood pressure reductions than vera
pamil SR. (C) 1997 American Journal of Hypertension, Ltd.